k7m2 (ATCC)
Structured Review

K7m2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 7742 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/k7m2/product/ATCC
Average 99 stars, based on 7742 article reviews
Images
1) Product Images from "αvβ3-targeted gas vesicles for ultrasound molecular imaging of tumors"
Article Title: αvβ3-targeted gas vesicles for ultrasound molecular imaging of tumors
Journal: Frontiers in Bioengineering and Biotechnology
doi: 10.3389/fbioe.2026.1808539
Figure Legend Snippet: In vitro cell targeting studies. (A–C) Flow cytometry assay of bEnd.3 cells, K7M2 cells and B16-F10 cells incubated with FITC-Con, FITC-RGD or free RGD + FITC-RGD, respectively. Representative fluorescent microscope images of bEnd.3 cells (D) , K7M2 cells (F) and B16-F10 cells (H) incubated with FITC-Con-hGVs, FITC-RGD-hGVs or free RGD + FITC-RGD-hGVs. Green stands for FITC, and blue for cell nuclei stained with DAPI. Scale bar: 50 µm. (E,G,I) represent the quantitative analysis of the fluorescence intensity in (D,F,H) , respectively. *** for P < 0.001; **** for P < 0.0001.
Techniques Used: In Vitro, Flow Cytometry, Incubation, Microscopy, Staining, Fluorescence
Figure Legend Snippet: In vivo ultrasound molecular imaging of tumors. (A) Nonlinear contrast images of Con-hGVs and RGD-hGVs were obtained at various time points after intravenous injection in K7M2 osteosarcoma and B16-F10 melanoma tumor-bearing mice. Time–intensity curves of Con-hGVs and RGD-hGVs after intravenous injection in K7M2 osteosarcoma–bearing mice (B) , and corresponding tumor signal intensities at 1, 3, 5, 7, and 10 min post-injection (C) . Time–intensity curves of Con-hGVs and RGD-hGVs after intravenous injection in B16-F10 tumor–bearing mice (D) , and corresponding tumor signal intensities at 1, 3, 5, 7, and 10 min post-injection (E) .
Techniques Used: In Vivo, Imaging, Injection
Figure Legend Snippet: Immunofluorescence and quantitative analysis of tumors. (A,B) Vascular immunofluorescence images and their quantification were obtained 600 s following the intravenous injection of FITC-labeled Con-hGVs or RGD-hGVs in K7M2 osteosarcoma-bearing mice. (C) The corresponding 3D surface plot graphs are presented in. (D,E) Vascular immunofluorescence images and quantification were acquired 600 s following the intravenous injection of FITC-labeled Con-hGVs or RGD-hGVs in B16-F10 melanoma-bearing mice, with the corresponding 3D surface plot graphs displayed in (F) .
Techniques Used: Immunofluorescence, Injection, Labeling
Figure Legend Snippet: Biosafety analysis. (A) Hemolysis testing of RGD-hGVs at OD 500 = 0.5, 1.0, 1.5, 2.0, 2.5, or 3.0, using Triton X-100 as the positive control and PBS as the negative control (n = 3). (B) Viability of bEnd.3, K7M2, and B16-F10 cells following exposure to RGD-hGVs at OD 500 = 0.5, 1.0, 1.5, 2.0, 2.5, or 3.0 for 6 h (n = 3). (C) H&E histology of major organs from mice administered Con-hGVs (OD 500 = 3.0), RGD-hGVs (OD 500 = 3.0), or PBS; scale bar, 200 μm. (D–G) Serum markers of hepatic function and renal function measured 7 days after injection of PBS, Con-hGVs, or RGD-hGVs (n = 3).
Techniques Used: Positive Control, Negative Control, Injection
